WO2004087880A3 - Composes et leur utilisation dans le traitement du diabete et troubles connexes - Google Patents

Composes et leur utilisation dans le traitement du diabete et troubles connexes Download PDF

Info

Publication number
WO2004087880A3
WO2004087880A3 PCT/US2004/009342 US2004009342W WO2004087880A3 WO 2004087880 A3 WO2004087880 A3 WO 2004087880A3 US 2004009342 W US2004009342 W US 2004009342W WO 2004087880 A3 WO2004087880 A3 WO 2004087880A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
related disorders
treat diabetes
diabetes
relates
Prior art date
Application number
PCT/US2004/009342
Other languages
English (en)
Other versions
WO2004087880A2 (fr
WO2004087880A8 (fr
Inventor
William H Bullock
Qingjie Liu
Original Assignee
Bayer Pharmaceuticals Corp
William H Bullock
Qingjie Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, William H Bullock, Qingjie Liu filed Critical Bayer Pharmaceuticals Corp
Priority to EP04758414A priority Critical patent/EP1613318A4/fr
Priority to US10/543,070 priority patent/US20060094714A1/en
Priority to JP2006509358A priority patent/JP2006521400A/ja
Publication of WO2004087880A2 publication Critical patent/WO2004087880A2/fr
Publication of WO2004087880A8 publication Critical patent/WO2004087880A8/fr
Publication of WO2004087880A3 publication Critical patent/WO2004087880A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

De façon générale, cette invention prote sur les composés décrits dans le descriptif. Plus précisément, elle concerne des composés et des compositions pharmaceutiques les renfermant. Sont décrites des méthodes d'administration d'un composé de l'invention pour le traitement du diabète et troubles connexes.
PCT/US2004/009342 2003-03-26 2004-03-26 Composes et leur utilisation dans le traitement du diabete et troubles connexes WO2004087880A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04758414A EP1613318A4 (fr) 2003-03-26 2004-03-26 Composes et leur utilisation dans le traitement du diabete et troubles connexes
US10/543,070 US20060094714A1 (en) 2004-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders
JP2006509358A JP2006521400A (ja) 2003-03-26 2004-03-26 糖尿病及び関連障害の処置のための化合物及びそれらの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45819403P 2003-03-26 2003-03-26
US60/458,194 2003-03-26

Publications (3)

Publication Number Publication Date
WO2004087880A2 WO2004087880A2 (fr) 2004-10-14
WO2004087880A8 WO2004087880A8 (fr) 2005-01-13
WO2004087880A3 true WO2004087880A3 (fr) 2005-03-10

Family

ID=33131765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009342 WO2004087880A2 (fr) 2003-03-26 2004-03-26 Composes et leur utilisation dans le traitement du diabete et troubles connexes

Country Status (3)

Country Link
EP (1) EP1613318A4 (fr)
JP (1) JP2006521400A (fr)
WO (1) WO2004087880A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2020006018A1 (fr) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Composés de naphtyridinone substitués utiles en tant qu'activateurs de lymphocytes t
CA3104647A1 (fr) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Composes de naphtyridinone utiles en tant qu'activateurs de lymphocytes t
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350817A (en) * 1980-02-28 1982-09-21 American Home Products Corporation 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
JPH07126268A (ja) * 1993-10-29 1995-05-16 Otsuka Pharmaceut Factory Inc １，８−ナフチリジン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
JP2007510649A (ja) * 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 置換ナフチリジノン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350817A (en) * 1980-02-28 1982-09-21 American Home Products Corporation 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
JPH07126268A (ja) * 1993-10-29 1995-05-16 Otsuka Pharmaceut Factory Inc １，８−ナフチリジン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] KUGE ET AL.: "A facile synthesis of 5-phenylimidazo[4,5-c][1,8]naphthyridine-4(5H)-one", XP002983823, accession no. STN Database accession no. 1995:257052 *
See also references of EP1613318A4 *
SYNTHETIC COMMUNICATIONS, vol. 24, no. 22, 1994, pages 3289 - 3296 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
EP1613318A2 (fr) 2006-01-11
WO2004087880A2 (fr) 2004-10-14
WO2004087880A8 (fr) 2005-01-13
JP2006521400A (ja) 2006-09-21
EP1613318A4 (fr) 2009-03-11

Similar Documents

Publication Publication Date Title
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2005046603A3 (fr) Composes pyridiniques
WO2005075425A3 (fr) Derives de bisaryluree
EP2305640A3 (fr) Diphenyl-éthers, -amines, -sulfides et -méthanes pour le traitement de maladies respiratoires
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
WO2005002515A3 (fr) Administration de composes therapeutiques au cerveau et a d'autres tissus
WO2007064883A3 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2005037798A3 (fr) Nouveaux composés
WO2006099943A8 (fr) 8-n-benzimidazoles a substitution amide, leur procede de production, et leur utilisation en tant que medicaments
WO2005080352A3 (fr) Derives de quinazoline et leur utilisation therapeutique
WO2004037789A3 (fr) Derives de methylene uree
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005082413A3 (fr) Combinaison de ciclesonide et de glycopyrronium
WO2002030405A3 (fr) Traitement de troubles affectifs par l'action combinee d'un agoniste du recepteur nicotinique et d'une substance monoaminergique
WO2005112923A3 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
WO2007006732A8 (fr) Combinaison synergique pour traiter une douleur (agoniste du recepteur canabinoide et agoniste du recepteur opioide)
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2005092062A3 (fr) Composes destines aux troubles neurodegeneratifs
WO2003087062A3 (fr) Composes heterocycliques, procede de preparation de ces composes et compositions pharmaceutiques les contenant, et utilisations en medecine
WO2006113718A3 (fr) Compositions destinees au traitement des neoplasmes
WO2004087880A3 (fr) Composes et leur utilisation dans le traitement du diabete et troubles connexes
WO2004098594A3 (fr) Forme posologique contenant du pantoprazole en tant qu'ingredient actif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 42/2004 UNDER "PUBLISHED" ADD "WITH DECLARATION"

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2006094714

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10543070

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006509358

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004758414

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004758414

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10543070

Country of ref document: US